English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduMost patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass., and published in the journal Thyroid.
Tag: Hyperthyroidism
Ichthyosis associated with greater risk of anxiety, depression
People living with Ichthyosis – a rare disorder with symptoms including dry, scaly patches of skin – may be at higher risk for mental health conditions like depression and anxiety, a new study finds. Researchers at Yale School of Medicine…
Radioactive iodine or surgery associated with increased survival in hyperthyroidism
Hyperthyroidism treatment like radioactive iodine or surgery was associated with a decreased risk for death, according to research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago.
First FDA-approved drug for thyroid eye disease effective regardless of age, gender
Teprotumumab, the first FDA-approved medicine for thyroid eye disease, provides significant improvement in eye bulging, regardless of patient gender, age or smoking status, according to a study accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
Cancer treatment with immune checkpoint inhibitors may lead to thyroid dysfunction
Thyroid dysfunction following cancer treatment with new treatments called immune checkpoint inhibitors is more common than previously thought, according to research that was accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society.